Skip to main content
DrugPrice

How It Works

How Drug Pricing Works in the U.S.

The U.S. spends more on prescription drugs than any other country — over $400 billion per year. Medicare Part D alone accounts for $355.8B across 1,613,400,000 claims. Here is how the money flows from manufacturer to your pharmacy counter, and why the price you pay has almost nothing to do with what the drug costs to make.

Step 1: The Manufacturer Sets a List Price

Every drug's pricing journey begins with the manufacturer setting the Wholesale Acquisition Cost (WAC) — the list price. In the United States, drug manufacturers can set this price at any level they choose. There is no government price control for most medications.

The list price has little connection to what the drug cost to develop or manufacture. It reflects what the market will bear — how much insurers and PBMs are willing to pay, factoring in competition, clinical benefit, and negotiating leverage. A drug that treats a condition with no alternatives can command a higher price than one competing against five generics.

Step 2: Wholesalers Buy and Distribute

Three wholesalers — McKesson, AmerisourceBergen, and Cardinal Health — distribute roughly 90% of all drugs sold in the U.S. They buy from manufacturers at or near WAC and sell to pharmacies with a small markup (typically 1-3%). Wholesalers operate on thin margins but enormous volume.

Step 3: PBMs Negotiate Rebates

Pharmacy Benefit Managers (PBMs) are the most powerful and controversial players in drug pricing. They negotiate rebates with manufacturers in exchange for favorable formulary placement.

Here's the key insight: a manufacturer may set a WAC of $500, then pay a 50% rebate back to the PBM, making the effective price $250. But the patient may still see the $500 list price when calculating their deductible. This disconnect between the "real" price (after rebates) and the price patients see is one of the most criticized aspects of the U.S. drug pricing system.

Step 4: Your Insurance Determines Your Cost

Your insurance plan's formulary determines which tier a drug is placed on — and therefore what you pay. Lower tiers (generics) have lower copays; higher tiers (specialty brands) have the highest cost-sharing.

If you're in the deductible phase of your coverage, you may pay the pharmacy's retail price — which can be shockingly high for brand-name drugs. Once past the deductible, you pay copays or coinsurance based on the tier.

Step 5: The Pharmacy Fills Your Prescription

The pharmacy buys the drug from a wholesaler, dispenses it to you, and bills your insurance (or the PBM, which processes the claim). The pharmacy's reimbursement is set by the PBM and is often lower than the pharmacy's acquisition cost for some drugs — a practice called "underwater reimbursement" that has driven many independent pharmacies out of business.

Why This System Produces High Prices

The U.S. drug pricing system is uniquely expensive because of several reinforcing factors:

  • No price regulation: Unlike every other developed country, the U.S. does not set or approve drug prices
  • Patent monopolies: Brand-name drugs face no price competition for 8-15 years after launch
  • Rebate opacity: PBM rebates reduce what insurers pay but don't always reduce what patients pay
  • Annual price increases: Manufacturers routinely raise prices 5-10% per year on existing drugs
  • Employer-based insurance: Because employers choose insurance plans, patients have limited ability to shop on price

What's Changing: The Inflation Reduction Act

The Inflation Reduction Act of 2022 is beginning to reshape this system. Medicare can now negotiate prices for high-cost drugs, price increases above inflation trigger manufacturer rebates, and out-of-pocket costs are capped at $2,000 per year. These changes primarily affect Medicare patients, but they may influence broader market dynamics over time.

Explore Drug Pricing Data

Frequently Asked Questions

The U.S. is one of the only developed countries that does not regulate drug prices. Manufacturers set prices unilaterally, and the traditional Medicare program was prohibited from negotiating until the Inflation Reduction Act of 2022. The complex supply chain — with PBMs, wholesalers, and pharmacies each taking a cut — adds opacity and cost. Additionally, patent protections and FDA exclusivity periods prevent generic competition for years after a drug launches.

A Pharmacy Benefit Manager (PBM) is a company that negotiates drug prices between manufacturers and insurers, manages formularies, and processes pharmacy claims. Three PBMs — CVS Caremark, Express Scripts, and OptumRx — control roughly 80% of the market. They negotiate rebates from manufacturers but critics argue they don't always pass savings to patients.

A drug's list price (WAC) is the manufacturer's sticker price before any discounts. Your cost depends on your insurance plan, formulary tier, deductible status, and any copay assistance. The actual price paid by your insurer is usually much lower than the list price due to PBM-negotiated rebates — sometimes 50-70% lower. But if you're in a deductible phase or uninsured, you may pay closer to the list price.